Corvex Management LP, together with director Keith A. Meister, reported acquiring shares of GeneDx Holdings Corp. Class A Common Stock in transactions executed on March 3 and March 5, 2026. The disclosed purchases total approximately $13.4 million and were completed at prices spanning from $70.34 to $82.06 per share.
The trades come as GeneDxs shares have fallen 38 percent over the prior six-month period. Despite the recent pullback in the stock price, analysts continue to publish bullish price targets for the company, with the range of expectations running from $130 to $177 per share.
GeneDx reported mixed fourth-quarter results that framed much of the recent analyst commentary. Revenue for the quarter was $121.0 million, representing a 27 percent increase year-over-year and narrowly exceeding the consensus estimate of $120.4 million. At the same time, the company missed on earnings for the period, a point some investors flagged as concerning during the earnings review.
Following the quarterly release and related investor calls, several equity research firms updated their targets and commentary while maintaining positive ratings. BTIG trimmed its price target to $170 from $200 but kept a Buy rating, citing a back-end loaded growth outlook. Canaccord Genuity reiterated its Buy rating with a $170 price target and noted that revenue from whole-exome sequencing and whole-genome sequencing, abbreviated WES/WGS, rose 32 percent year-over-year. TD Cowen likewise maintained a Buy rating and set a $165 price target, referencing the companys projected growth in genetic testing and planned product expansions by 2026.
The mix of continued insider buying, recent revenue outperformance versus consensus, and the divergence between price targets and current share price has produced a range of analyst views. Collectively, the recent developments underscore a varied sentiment among market participants and research analysts about GeneDxs near-term earnings trajectory and longer-term growth prospects.
Summary of the key facts
- Purchasers: Corvex Management LP and director Keith A. Meister.
- Security: GeneDx Holdings Corp. Class A Common Stock (NASDAQ: WGS).
- Transaction dates: March 3 and March 5, 2026.
- Total disclosed value: Approximately $13.4 million.
- Price range: $70.34 to $82.06 per share.
- Recent stock movement: Down 38 percent over six months.
- Analyst price targets: $130 to $177 per share.
- Q4 results: Revenue $121.0 million, up 27 percent year-over-year; consensus was $120.4 million; earnings missed expectations.
- Notable analyst actions: BTIG lowered its target to $170 from $200 but kept a Buy; Canaccord Genuity kept Buy and $170 target, citing 32 percent WES/WGS revenue growth; TD Cowen kept Buy with a $165 target and cited growth and product expansion plans by 2026.